Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cayman Chemical Company Inc","sponsor":"NIDCR","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Cayman Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical"},{"orgOrder":0,"company":"Cayman Chemical Company Inc","sponsor":"SBIR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cayman Receives SBIR Grant for Alzheimer\u2019s Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cayman Pharma s.r.o","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cayman Update on its Dental Implant candidate KMN-159 for Osseointegration","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"CZECH REPUBLIC","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Cayman Pharma s.r.o

    Menu

    Cayman Pharma s.r.o

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cayman Pharma s.r.o

              Contact Supplier
              • Development Update
              Virtual BoothCayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.
              Contact Supplier Contact Supplier
              Flag Czech Republic
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cayman Update on its Dental Implant candidate KMN-159 for Osseointegration

              Details:

              KMN-159 is a potent, stable, and a highly selective EP4 receptor agonist that stimulates osteogenic activity. It is being evaluated for the treatment of osteoporosis.

              Lead Product(s): KMN-159

              Therapeutic Area: Musculoskeletal Product Name: KMN-159

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 04, 2023

              Cayman

              BIO Int. Convention

              Booth# 3740

              envelop Contact Supplier

              Cayman Chemical Company Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cayman Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration

              Details:

              The grant will be used to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage of dental titanium implants into the jawbone.

              Lead Product(s): KMN-159,Collagen

              Therapeutic Area: Musculoskeletal Product Name: KMN-159

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: NIDCR

              Deal Size: $1.7 million Upfront Cash: Undisclosed

              Deal Type: Funding September 16, 2021

              Cayman

              Iran Expo

              Not Confirmed

              envelop Contact Supplier

              Cayman Chemical Company Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cayman Receives SBIR Grant for Alzheimer’s Research

              Details:

              The funding will be used to develop an assay platform and novel antibodies to support the treatment, prevention, and early diagnosis of Alzheimer’s disease and other tauopathies.

              Lead Product(s): Antibody

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: SBIR

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding October 08, 2020

              Cayman

              Iran Expo

              Not Confirmed

              envelop Contact Supplier
              Cayman pharma
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY